Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News International Stem Cell Corp ISCO

Healthcare Biotechnology
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central... see more

Recent & Breaking News (OTCQB:ISCO)

International Stem Cell Corporation Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC

GlobeNewswire July 28, 2016

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease

PR Newswire May 23, 2016

International Stem Cell Corporation Announces 2015 Fourth Quarter and Year-End Results

Marketwired March 31, 2016

International Stem Cell Corporation to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial

Marketwired March 10, 2016

International Stem Cell Corporation Announces Commencement of Enrollment of Phase I Trial of ISC-hpNSC

Marketwired March 7, 2016

International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health

Marketwired December 23, 2015

International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease

Marketwired December 14, 2015

International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015

Marketwired November 16, 2015

International Stem Cell Corporation Moves Forward With Parkinson's Disease Clinical Trials in Australia

Marketwired November 3, 2015

International Stem Cell Corporation Presents Comprehensive Findings for Parkinson's Disease Program Preclinical Studies at the Society for Neuroscience Annual Meeting, Neuroscience 2015

Marketwired October 14, 2015

International Stem Cell Corporation Develops Technology to Replace Cartilage for the Treatment of Osteoarthritis

Marketwired September 30, 2015

International Stem Cell Names Ms. Ebrahimi as Chief Financial Officer

Marketwired September 22, 2015

International Stem Cell Corporation Announces Next Phase of Research Collaboration With Rohto Pharmaceutical Co., Ltd. of Japan

Marketwired September 8, 2015

International Stem Cell Corporation to Present at the Rodman and Renshaw Global Investment Conference

Marketwired September 1, 2015